Advertisement
Screener

VERTEX PHARMACEUTICALS INC / MA (VRTX) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

VERTEX PHARMACEUTICALS INC / MA Financing Cash Flow

VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Financing Cash Flow of -$965.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-04

  • VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$426.70M.
  • VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$538.80M.
  • VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$77.20M.
  • VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$1.15B.
  • VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) financing activities for fiscal 2025 was -$2.26B.
  • VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) financing activities for fiscal 2024 was -$1.49B.
  • VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) financing activities for fiscal 2023 was -$562.20M.
  • VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) financing activities for fiscal 2022 was -$67.70M.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 3 month as first filedNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 6 month as first filedNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 9 month as first filedNet Cash Provided by (Used in) Financing Activities 12 monthNet Cash Provided by (Used in) Financing Activities 12 month as first filed
2026-06-30-$426.70M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
-$965.50M
10-Q · filed 2026-08-04
-$1.04B
derived: sum of 3 quarters · filed 2026-08-04
-$2.20B
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31-$538.80M
10-Q · filed 2026-05-05
-$616.00M
derived: sum of 2 quarters · filed 2026-05-05
-$1.77B
derived: sum of 3 quarters · filed 2026-05-05
-$2.12B
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31-$77.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13
-$1.23B
derived: sum of 2 quarters · filed 2026-02-13
-$1.58B
derived: sum of 3 quarters · filed 2026-08-04
-$2.26B
10-K · filed 2026-02-13
2025-09-30-$1.15B
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$1.50B
derived: sum of 2 quarters · filed 2026-08-04
-$2.18B
10-Q · filed 2025-11-04
-$2.58B
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30-$349.20M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
-$1.03B
10-Q · filed 2026-08-04
-$1.42B
derived: sum of 3 quarters · filed 2026-08-04
-$1.81B
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31-$680.40M
10-Q · filed 2026-05-05
-$1.07B
derived: sum of 2 quarters · filed 2026-05-05
-$1.46B
derived: sum of 3 quarters · filed 2026-05-05
-$1.82B
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31-$391.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13
-$778.80M
derived: sum of 2 quarters · filed 2026-02-13
-$1.14B
derived: sum of 3 quarters · filed 2026-02-13
-$1.49B
10-K · filed 2026-02-13
2024-09-30-$387.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$746.10M
derived: sum of 2 quarters · filed 2025-11-04
-$1.10B
10-Q · filed 2025-11-04
-$1.22B
derived: sum of 4 quarters · filed 2026-02-13
2024-06-30-$358.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05
-$716.10M
10-Q · filed 2025-08-05
-$835.90M
derived: sum of 3 quarters · filed 2026-02-13
-$1.00B
derived: sum of 4 quarters · filed 2026-02-13
2024-03-31-$357.50M
10-Q · filed 2025-05-06
-$477.30M
derived: sum of 2 quarters · filed 2026-02-13
-$642.30M
derived: sum of 3 quarters · filed 2026-02-13
-$625.00M
derived: sum of 4 quarters · filed 2026-02-13
2023-12-31-$119.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13
-$284.80M
derived: sum of 2 quarters · filed 2026-02-13
-$267.50M
derived: sum of 3 quarters · filed 2026-02-13
-$562.20M
10-K · filed 2026-02-13
2023-09-30-$165.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05
-$147.70M
derived: sum of 2 quarters · filed 2024-11-05
-$442.40M
10-Q · filed 2024-11-05
-$402.20M
derived: sum of 4 quarters · filed 2025-02-13
2023-06-30$17.30M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02
-$277.40M
10-Q · filed 2024-08-02
-$237.20M
derived: sum of 3 quarters · filed 2025-02-13
-$297.40M
derived: sum of 4 quarters · filed 2025-02-13
2023-03-31-$294.70M
10-Q · filed 2024-05-07
-$254.50M
derived: sum of 2 quarters · filed 2025-02-13
-$314.70M
derived: sum of 3 quarters · filed 2025-02-13
-$267.00M
derived: sum of 4 quarters · filed 2025-02-13
2022-12-31$40.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13
-$20.00M
derived: sum of 2 quarters · filed 2025-02-13
$27.70M
derived: sum of 3 quarters · filed 2025-02-13
-$67.70M
10-K · filed 2025-02-13
2022-09-30-$60.20M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07
-$12.50M
derived: sum of 2 quarters · filed 2023-11-07
-$107.90M
10-Q · filed 2023-11-07
-$444.10M
derived: sum of 4 quarters · filed 2024-02-15
2022-06-30$47.70M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02
-$47.70M
10-Q · filed 2023-08-02
-$383.90M
derived: sum of 3 quarters · filed 2024-02-15
-$1.04B
derived: sum of 4 quarters · filed 2024-02-15
2022-03-31-$95.40M
10-Q · filed 2023-05-02
-$431.60M
derived: sum of 2 quarters · filed 2024-02-15
-$1.09B
derived: sum of 3 quarters · filed 2024-02-15
-$1.05B
derived: sum of 4 quarters · filed 2024-02-15
2021-12-31-$336.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15
-$992.90M
derived: sum of 2 quarters · filed 2024-02-15
-$959.30M
derived: sum of 3 quarters · filed 2024-02-15
-$1.48B
10-K · filed 2024-02-15
2021-09-30-$656.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28
-$623.10M
derived: sum of 2 quarters · filed 2022-10-28
-$1.14B
10-Q · filed 2022-10-28
-$1.14B
10-Q · filed 2021-11-03
-$1.27B
derived: sum of 4 quarters · filed 2023-02-10
2021-06-30$33.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05
-$485.10M
10-Q · filed 2022-08-05
-$485.10M
10-Q · filed 2021-07-30
-$610.31M
derived: sum of 3 quarters · filed 2023-02-10
-$751.00M
derived: sum of 4 quarters · filed 2023-02-10
2021-03-31-$518.70M
10-Q · filed 2022-05-06
-$518.65M
10-Q · filed 2021-04-30
-$643.91M
derived: sum of 2 quarters · filed 2023-02-10
-$784.60M
derived: sum of 3 quarters · filed 2023-02-10
-$664.57M
derived: sum of 4 quarters · filed 2023-02-10
2020-12-31-$125.21M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10
-$265.89M
derived: sum of 2 quarters · filed 2023-02-10
-$145.87M
derived: sum of 3 quarters · filed 2023-02-10
-$505.30M
10-K · filed 2023-02-10
-$505.28M
10-K · filed 2021-02-11
2020-09-30-$140.68M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03
-$20.66M
derived: sum of 2 quarters · filed 2021-11-03
-$380.09M
10-Q · filed 2021-11-03
-$218.64M
derived: sum of 4 quarters · filed 2022-02-09
2020-06-30$120.03M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30
-$239.41M
10-Q · filed 2021-07-30
-$77.96M
derived: sum of 3 quarters · filed 2022-02-09
-$57.60M
derived: sum of 4 quarters · filed 2022-02-09
2020-03-31-$359.43M
10-Q · filed 2021-04-30
-$197.98M
derived: sum of 2 quarters · filed 2022-02-09
-$177.63M
derived: sum of 3 quarters · filed 2022-02-09
-$190.64M
derived: sum of 4 quarters · filed 2022-02-09
2019-12-31$161.45M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09
$181.80M
derived: sum of 2 quarters · filed 2022-02-09
$168.79M
derived: sum of 3 quarters · filed 2022-02-09
$126.80M
10-K · filed 2022-02-09
$126.77M
10-K · filed 2020-02-13
2019-09-30$20.36M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30
$7.34M
derived: sum of 2 quarters · filed 2020-10-30
-$34.65M
10-Q · filed 2020-10-30
-$135.69M
derived: sum of 4 quarters · filed 2021-02-11
2019-06-30-$13.02M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31
-$55.00M
10-Q · filed 2020-07-31
-$156.05M
derived: sum of 3 quarters · filed 2021-02-11
-$153.97M
derived: sum of 4 quarters · filed 2021-02-11
2019-03-31-$41.99M
10-Q · filed 2020-05-01
-$143.03M
derived: sum of 2 quarters · filed 2021-02-11
-$140.96M
derived: sum of 3 quarters · filed 2021-02-11
-$192.16M
derived: sum of 4 quarters · filed 2021-02-11
2018-12-31-$101.05M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11
-$98.97M
derived: sum of 2 quarters · filed 2021-02-11
-$150.18M
derived: sum of 3 quarters · filed 2021-02-11
-$71.22M
10-K · filed 2021-02-11
2018-09-30$2.08M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31
-$49.13M
derived: sum of 2 quarters · filed 2019-10-31
$29.83M
10-Q · filed 2019-10-31
$103.06M
derived: sum of 4 quarters · filed 2020-02-13
2018-06-30-$51.21M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01
$27.75M
10-Q · filed 2019-08-01
$100.98M
derived: sum of 3 quarters · filed 2020-02-13
$253.68M
derived: sum of 4 quarters · filed 2020-02-13
2018-03-31$78.96M
10-Q · filed 2019-05-01
$152.19M
derived: sum of 2 quarters · filed 2020-02-13
$304.89M
derived: sum of 3 quarters · filed 2020-02-13
$436.93M
derived: sum of 4 quarters · filed 2020-02-13
2017-12-31$73.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13
$225.94M
derived: sum of 2 quarters · filed 2020-02-13
$357.97M
derived: sum of 3 quarters · filed 2020-02-13
$68.40M
10-K · filed 2020-02-13
2017-09-30$152.71M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25
$284.74M
derived: sum of 2 quarters · filed 2018-10-25
-$4.83M
10-Q · filed 2018-10-25
$88.94M
derived: sum of 4 quarters · filed 2019-02-13
2017-06-30$132.03M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26
-$157.53M
10-Q · filed 2018-07-26
-$63.77M
derived: sum of 3 quarters · filed 2019-02-13
-$50.22M
derived: sum of 4 quarters · filed 2019-02-13
2017-03-31-$289.56M
10-Q · filed 2018-04-27
-$195.80M
derived: sum of 2 quarters · filed 2019-02-13
-$182.25M
derived: sum of 3 quarters · filed 2019-02-13
-$161.00M
derived: sum of 4 quarters · filed 2019-02-13
2016-12-31$93.76M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13
$107.32M
derived: sum of 2 quarters · filed 2019-02-13
$128.57M
derived: sum of 3 quarters · filed 2019-02-13
$133.27M
10-K · filed 2019-02-13
2016-09-30$13.55M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-30
$34.81M
derived: sum of 2 quarters · filed 2017-10-30
$39.51M
10-Q · filed 2017-10-30
$92.15M
derived: sum of 4 quarters · filed 2018-02-15
2016-06-30$21.25M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28
$25.95M
10-Q · filed 2017-07-28
$78.59M
derived: sum of 3 quarters · filed 2018-02-15
$128.26M
derived: sum of 4 quarters · filed 2018-02-15
2016-03-31$4.70M
10-Q · filed 2017-04-28
$57.34M
derived: sum of 2 quarters · filed 2018-02-15
$107.01M
derived: sum of 3 quarters · filed 2018-02-15
$143.21M
derived: sum of 4 quarters · filed 2018-02-15
2015-12-31$52.64M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15
$102.31M
derived: sum of 2 quarters · filed 2018-02-15
$138.50M
derived: sum of 3 quarters · filed 2018-02-15
$188.92M
10-K · filed 2018-02-15
2015-09-30$49.67M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-31
$85.86M
derived: sum of 2 quarters · filed 2016-10-31
$136.28M
10-Q · filed 2016-10-31
$91.12M
10-Q · filed 2015-10-30
2015-06-30$36.20M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01
$86.61M
10-Q · filed 2016-08-01
2015-03-31$50.41M
10-Q · filed 2016-05-03
2014-09-30$441.05M
10-Q · filed 2015-10-30
2011-06-30$55.03M
derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-09
$38.67M
10-Q · filed 2011-08-09
$48.12M
derived: sum of 3 quarters · filed 2011-08-09
$446.62M
derived: sum of 4 quarters · filed 2011-08-09
2011-03-31-$16.36M
10-Q · filed 2011-05-06
-$6.91M
derived: sum of 2 quarters · filed 2011-05-06
$391.58M
derived: sum of 3 quarters · filed 2011-05-06
$401.06M
derived: sum of 4 quarters · filed 2011-08-09
2010-12-31$9.45M
derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-17
$407.94M
derived: sum of 2 quarters · filed 2011-02-17
$417.42M
derived: sum of 3 quarters · filed 2011-08-09
$425.06M
10-K · filed 2011-02-17
2010-09-30$398.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28
$407.97M
derived: sum of 2 quarters · filed 2011-08-09
$415.61M
10-Q · filed 2010-10-28
$954.27M
derived: sum of 4 quarters · filed 2011-08-09
2010-06-30$9.47M
derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-09
$17.11M
10-Q · filed 2011-08-09
$555.78M
derived: sum of 3 quarters · filed 2011-08-09
$686.37M
derived: sum of 4 quarters · filed 2011-08-09
2010-03-31$7.64M
10-Q · filed 2011-05-06
$546.31M
derived: sum of 2 quarters · filed 2011-05-06
$676.90M
derived: sum of 3 quarters · filed 2011-05-06
$687.98M
derived: sum of 4 quarters · filed 2011-05-06
2009-12-31$538.66M
derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-17
$669.26M
derived: sum of 2 quarters · filed 2011-02-17
$680.34M
derived: sum of 3 quarters · filed 2011-02-17
$999.01M
10-K · filed 2011-02-17
2009-09-30$130.59M
derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28
$141.67M
derived: sum of 2 quarters · filed 2010-10-28
$460.34M
10-Q · filed 2010-10-28
2009-06-30$11.08M
derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-03
$329.75M
10-Q · filed 2010-08-03
2009-03-31$318.67M
10-Q · filed 2010-05-03
2008-12-31$620.74M
10-K · filed 2011-02-17

Similar stocks

Stock NameCountryMarket CapPE Ratio
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
PFIZER INC (PFE)United States$162.042B31.94
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64